2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T

Phase 1positiveRD140Positive

AI Analysis

Summary

IASO Bio presented first-in-human Phase 1 data for RD140, a fully human BCMA/GPRC5D dual-targeted FasT CAR-T, in 9 heavily pretreated patients with relapsed/refractory multiple myeloma or plasma cell leukemia at the 2026 IMS conference.

Clinical Trial Data

Phase

Phase 1

Patients

Outcome Details

First-in-human Phase 1 data presented in 9 heavily pretreated, high-risk patients with relapsed/refractory multiple myeloma or plasma cell leukemia

Importance:6/10

Sentiment:

0.60

CAR-Tdual-targetedBCMAGPRC5Dmultiple myelomaplasma cell leukemiafirst-in-human

Related Companies

$TRAX

Read the original article

Published by PR Newswire Pharma on September 25, 2026 3:32 PM

Read Original